WorldWideScience
 
 
1

Comparative pharmacokinetics of two prodrugs of zidovudine in rabbits: enhanced levels of zidovudine in brain tissue.  

UK PubMed Central (United Kingdom)

The pharmacokinetics of two prodrugs of zidovudine (AZT), 1,4-dihydro-1-methyl-3-[(pyridylcarbonyl)oxy] ester and isoleucinyl ester (DPAZT and IAZT, respectively), were investigated in a rabbit model...Full Text Available

1993-04-01

2

An improved synthesis of [5'-"3H]-3'-azido-3'-deoxythymidine, tritiated Zidovudine  

International Nuclear Information System (INIS)

[5'-"3H]-3'-Azido-3'-deoxythymidine (3) was prepared at a specific activity of 14.0 Ci/mmol by a two-step synthetic sequence involving controlled oxidation of the unlabelled compound (1) to the 5'-aldehyde (2) followed by reduction with ["3H]-NaBH_4. Purification was performed by preparative TLC. The radiochemical purity was 99.2%. (author).

3

Reversal of brain metabolic abnormalities following treatment of AIDS dementia complex with 3'-azido-2',3'-dideoxythymidine (AZT, zidovudine): a PET-FDG study  

International Nuclear Information System (INIS)

Brain glucose metabolism was evaluated in four patients with acquired immunodeficiency syndrome (AIDS) dementia complex using ["1"8F]fluorodeoxyglucose (FDG) and positron emission tomography (PET) scans at the beginning of therapy with 3'-azido-2',3'-dideoxythymidine (AZT, zidovudine), and later in the course of therapy. In two patients, baseline, large focal cortical abnormalities of glucose utilization were reversed during the course of therapy. In the other two patients, the initial PET study did not reveal pronounced focal alterations, while the post-treatment scans showed markedly increased cortical glucose metabolism. The improved cortical glucose utilization was accompanied in all patients by immunologic and neurologic improvement. PET-FDG studies can detect cortical metabolic abnormalities associated with AIDS dementia complex, and may be used to monitor the metabolic improvement in response to AZT treatment.